Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palisade Bio (PALI – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Palisade Bio (PALI)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Palisade Bio yesterday and set a price target of $8.00. The company’s shares closed last Tuesday at $1.73, close to its 52-week low of $0.65.
According to TipRanks.com, Rahman is ranked 0 out of 5 stars with an average return of
Palisade Bio has an analyst consensus of Strong Buy, with a price target consensus of $13.00.
See Insiders’ Hot Stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Apellis Pharmaceuticals, with a price target of $45.00. The company’s shares closed last Tuesday at $22.25.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Apellis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $31.69.
